Application of traditional Chinese medicine composition in preparation of medicine for treating prostate diseases
By combining Cistanche deserticola, ginseng, Rehmannia glutinosa, Astragalus membranaceus, Poria cocos, and maca, this method solves the problem that existing Chinese herbal compound prescriptions are difficult to treat both the symptoms and the root cause of benign prostatic hyperplasia, and achieves the effect of significantly reducing prostate volume and improving urinary symptoms.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-11
- Publication Date
- 2026-04-10
AI Technical Summary
Existing Chinese herbal formulas for treating benign prostatic hyperplasia mostly focus on promoting blood circulation and removing blood stasis or tonifying the kidneys, while neglecting to strengthen the spleen and remove dampness. This makes it difficult to fundamentally regulate the pathogenesis of "deficiency of both kidney and spleen, and mutual binding of phlegm and blood stasis," resulting in unstable efficacy or easy recurrence.
This treatment uses a combination of Cistanche deserticola, ginseng, Rehmannia glutinosa, Astragalus membranaceus, Poria cocos, and maca. It nourishes Yin and tonifies the kidneys, strengthens the spleen and eliminates dampness, resolves phlegm and promotes urination, improves the Qi transformation function of the lower Jiao, promotes water metabolism, softens and dissipates phlegm and blood stasis in the prostate, and achieves the effect of treating both the symptoms and the root cause.
It significantly reduces prostate volume, improves urination symptoms, enhances the treatment effect of benign prostatic hyperplasia, has few side effects, and addresses both the symptoms and the root cause.
Smart Images
Figure SMS_1
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of traditional Chinese medicine, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating prostatitis. BACKGROUND
[0002] Prostatic hyperplasia is a common and frequently-occurring disease of middle-aged and elderly men, and its incidence increases with age. The disease is characterized by hyperplasia of prostatic glands and interstitial cells, and is mainly manifested in lower urinary tract symptoms, such as frequent urination, urinary urgency, nocturia, hesitancy, dysuria, thin stream of urine and incomplete voiding, etc. In severe cases, it can cause urinary retention and renal function damage, and seriously affect the quality of life of patients.
[0003] Modern medical treatment of prostatic hyperplasia mainly includes drug therapy and surgical treatment. Drug therapy mainly uses alpha-receptor blockers (such as tamsulosin) and 5-alpha-reductase inhibitors (such as finasteride). The former relaxes the smooth muscle of the prostate and bladder neck to improve voiding symptoms, and the latter inhibits the conversion of androgens to dihydrotestosterone to reduce the volume of the prostate. However, alpha-receptor blockers often have side effects such as orthostatic hypotension and dizziness, and cannot prevent disease progression; 5-alpha-reductase inhibitors have a slow onset and can cause sexual dysfunction. Surgical treatment has a clear effect, but has risks such as trauma, bleeding, infection and retrograde ejaculation, and patients have different acceptance.
[0004] Traditional Chinese medicine has unique advantages in the treatment of prostatic hyperplasia, which is classified into the categories of “Jinglao” and “Lanbi”. Traditional Chinese medicine theory believes that the core pathogenesis of the disease is deficiency in origin and excess in superficiality. “Shen zhi shui, si er bian”, after men enter middle age, kidney qi gradually becomes deficient, and gasification is weak, which causes abnormal urination; “Pi zhu yunhua”, if the spleen is deficient, water and dampness will be retained inside and condensed into phlegm turbidity; kidney deficiency and spleen deficiency can both cause blood stasis due to poor blood circulation. Pathological products such as phlegm, dampness and stasis are mutually combined, blocked in the lower energizer, and condensed in the Jing room (prostate), forming a mass, i.e. prostatic hyperplasia. Therefore, “deficiency of both kidney and spleen and mutual combination of phlegm and stasis” is the key pathogenesis of the occurrence and development of prostatic hyperplasia. At present, although there are many traditional Chinese medicine compounds for treating prostatic hyperplasia, most of the prescriptions either excessively emphasize blood-activating and stasis-removing, softening and resolving, and are too aggressive and easy to harm healthy qi; or excessively emphasize kidney tonification and ignore spleen invigoration, phlegm-eliminating and dampness-removing, and are difficult to fundamentally regulate the complex pathogenesis of “deficiency of both kidney and spleen and mutual combination of phlegm and stasis”, resulting in unstable efficacy or easy recurrence. Therefore, it is necessary to improve the existing technology and provide a traditional Chinese medicine composition which can achieve treatment of both symptoms and root causes, attack and tonification, and has stable efficacy and few side effects. SUMMARY
[0005] The inventors of the present application accidentally found that the medicine of the application number 2026100913949 is very effective for improving male prostate diseases when the medicine is applied to improve sperm quality to treat male infertility. Therefore, the inventors further researched the preparation of the traditional Chinese medicine composition for the treatment of prostate diseases, especially prostate hyperplasia, and applied the composition to the treatment of prostate diseases. The application of the traditional Chinese medicine composition in the preparation of a medicine for treating prostate diseases, the traditional Chinese medicine composition is composed of the following raw materials by weight: Cistanche extract 20-40 parts, ginseng extract 10-15 parts, prepared rehmannia root extract 40-50 parts, astragalus extract 20-30 parts, poria extract 20-30 parts, and maca extract 1-2 parts.
[0006] Preferably, the traditional Chinese medicine composition is composed of the following raw materials by weight: Cistanche extract 30 parts, ginseng extract 10 parts, prepared rehmannia root extract 45 parts, astragalus extract 25 parts, poria extract 25 parts, and maca extract 1 part.
[0007] Preferably, the traditional Chinese medicine composition is composed of the following raw materials by weight: Cistanche extract 20 parts, ginseng extract 15 parts, prepared rehmannia root extract 50 parts, astragalus extract 25 parts, poria extract 30 parts, and maca extract 2 parts.
[0008] Further, the cistanche extract, ginseng extract, prepared rehmannia root extract, astragalus extract, poria extract, and maca extract are respectively prepared by extracting the raw materials with a solvent, and then concentrating and drying the extract.
[0009] Further, the solvent is water, alcohol, or an aqueous alcohol solution.
[0010] Further, the ginseng extract is replaced by red ginseng extract.
[0011] Further, the prostate disease includes prostate hyperplasia.
[0012] Based on the same inventive concept, the present application also provides a medicine for treating prostate diseases, which is prepared from the following raw materials by weight: Cistanche extract 20-40 parts, ginseng extract 10-15 parts, prepared rehmannia root extract 40-50 parts, astragalus extract 20-30 parts, poria extract 20-30 parts, and maca extract 1-2 parts.
[0013] Preferably, the traditional Chinese medicine composition is composed of the following raw materials by weight: Cistanche extract 30 parts, ginseng extract 10 parts, prepared rehmannia extract 45 parts, astragalus extract 25 parts, poria extract 25 parts, and maca extract 1 part.
[0014] Preferably, the cistanche extract, ginseng extract, prepared rehmannia extract, astragalus extract, poria extract, and maca extract are respectively prepared by extracting raw materials with a solvent, and then drying the extract.
[0015] The present application has the following beneficial effects: The present application applies the traditional Chinese medicine for treating male infertility by improving sperm quality to treating prostate, especially prostate hyperplasia, and finds that the treatment effect is remarkable. The traditional Chinese medicine composition of the present application is highly consistent with the pathogenesis of prostate diseases, especially prostate hyperplasia, and has a reasonable mechanism of action. The pathogenesis of prostate hyperplasia mainly lies in deficiency of both kidney and spleen and mutual accumulation of phlegm and blood stasis. The prepared rehmannia and poria are main drugs. The prepared rehmannia nourishes yin and tonifies kidney, fills essence and benefits marrow, and can solve the problem of weak gasification from the root of kidney. The poria invigorates spleen and dries dampness, removes phlegm and diuresis, and regulates water passage. It can not only help the spleen to transport and transform to cut off the source of phlegm, but also directly relieve dysuria. At the same time, its dampness-drying nature can restrict the greasiness of the prepared rehmannia. The two drugs complement each other. The cistanche, astragalus, and ginseng are auxiliary drugs. The cistanche tonifies kidney yang and benefits essence and blood, and cooperates with the prepared rehmannia to achieve yin and yang tonification, providing motive power for the gasification of lower energizer. The astragalus and ginseng greatly tonify primordial qi, invigorate the spleen and benefit qi, strengthen the acquired constitution, help the poria to enhance the transport and transformation function of the spleen, and then provide the kidney essence with sufficient nourishment, promote blood circulation and transport and transform water and dampness, and add maca to tonify kidney and resist fatigue, which can assist the main and auxiliary drugs to enhance the overall function. The combination of all drugs in the whole prescription can tonify kidney and invigorate spleen to consolidate the root, dry dampness and remove phlegm, activate blood and resolve stasis to treat the symptoms, improve the gasification function of lower energizer, promote water and liquid metabolism, soften and disperse the phlegm, blood stasis, and stasis of prostate, thereby effectively reducing the volume of prostate and improving the symptoms of urination, achieving the purpose of treating prostate hyperplasia, attacking evil without damaging normal qi, tonifying deficiency without being attached to evil, and treating both symptoms and root. DETAILED DESCRIPTION
[0016] To make the objectives, technical solutions, and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be described below in detail with reference to the embodiments of the present application. Obviously, the described embodiments are only some of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative work fall within the scope of protection of the present application.
[0017] Embodiment 1: A traditional Chinese medicine composition, which is composed of the following raw materials: Cistanche extract 30 parts, ginseng extract 10 parts, prepared rehmannia extract 45 parts, astragalus extract 25 parts, poria extract 25 parts, and maca extract 1 part.
[0018] Example 2: a traditional Chinese medicine composition made from the following raw materials: Cistanche extract 20 parts, ginseng extract 15 parts, prepared rehmannia extract 50 parts, astragalus extract 25 parts, poria extract 30 parts, and maca extract 2 parts.
[0019] The Cistanche extract, ginseng extract, prepared rehmannia extract, astragalus extract, poria extract, and maca extract used in Example 1 and Example 2 can be directly purchased, or can be prepared by extracting the raw materials with a solvent, and then concentrating and drying the extract.
[0020] Specifically, the Cistanche extract, ginseng extract, prepared rehmannia extract, astragalus extract, poria extract, and maca extract are prepared by extracting with an ethanol solution, and then concentrating and drying.
[0021] The specific preparation operation steps are as follows.
[0022] ①The preparation operation of the Cistanche extract is as follows: Dry Cistanche is taken, impurities are removed, and then pulverized and passed through a 20-mesh sieve; To the Cistanche powder, 6-8 times the amount of 70% ethanol by weight is added, and under reflux conditions, heated at 80±2°C for 1.5 hours for alcohol extraction. After filtration, the filter cake is added with 6-8 times the amount of 70% ethanol by weight, and under reflux conditions, heated at 80±2°C for 1.5 hours for alcohol extraction. After filtration, the two filtrates are combined; The combined filtrate is concentrated under vacuum at 60°C to a thick paste with a relative density of about 1.10-1.15 (60°C).
[0023] The thick paste is vacuum dried at 75°C to obtain Cistanche extract powder.
[0024] ②The preparation operation of the ginseng extract is as follows: Freshly dried ginseng is taken, cleaned, pulverized, and passed through a 20-mesh sieve; To the ginseng powder, 8-10 times the amount of 70% ethanol by weight is added, and under reflux conditions, heated at 80±2°C for 2 hours for alcohol extraction. After filtration, the filter cake is added with 6-8 times the amount of 70% ethanol by weight, and under reflux conditions, heated at 80±2°C for 2 hours for alcohol extraction. After filtration, the filter cake is again added with 6-8 times the amount of 70% ethanol by weight, and under reflux conditions, heated at 80±2°C for 2 hours for alcohol extraction. After filtration, the three filtrates are combined; The combined filtrate was concentrated under reduced pressure at 60°C to a thick paste with a relative density of about 1.2 (60°C); The thick paste was vacuum dried at 75°C to obtain the powder of the Rehmannia glutinosa extract.
[0025] The Rehmannia glutinosa extract was prepared as follows: The Rehmannia glutinosa was cleaned and impurities were removed, and then ground and passed through a 20-mesh sieve; The Rehmannia glutinosa powder was added with 8-10 times the weight of 70% ethanol, and heated under reflux at 80±2°C for 1.5 h. The filtrate was collected. The filtrate was added with 6-8 times the weight of 70% ethanol, and heated under reflux at 80±2°C for 1.5 h. The filtrate was collected. The combined filtrate was concentrated under reduced pressure at 60°C to a thick paste with a relative density of about 1.10-1.15 (60°C).
[0026] The thick paste was vacuum dried at 75°C to obtain the powder of the Rehmannia glutinosa extract.
[0027] The Rehmannia glutinosa extract was prepared as follows:
[0028] The traditional Chinese medicine composition of Example 1 and Example 2 was prepared into a capsule, and the preparation was as follows: The raw materials were weighed and ground, and then passed through an 80-100-mesh sieve. The ground materials were mixed, and then filled into capsules. Each capsule contained 1 g.
[0029] Comparative Example 1: A traditional Chinese medicine composition was prepared from the following raw materials: Cistanche tubulosa extract 30 parts, Panax ginseng extract 10 parts, Rehmannia glutinosa extract 45 parts, Astragalus membranaceus extract 25 parts, Coix seed extract 25 parts, and Maca extract 1 part.
[0030] In this comparative example, the Coix seed extract was used to replace the same amount of the Poria cocos extract.
[0031] The Coix seed extract was prepared as follows:
[0032] Comparative Example 2: A traditional Chinese medicine composition was prepared from the following raw materials: Cistanche tubulosa extract 30 parts, Panax ginseng extract 10 parts, Rehmannia glutinosa extract 45 parts, Astragalus membranaceus extract 25 parts, Poria cocos extract 25 parts, and Maca extract 1 part.
[0033] In this comparative example, the Rhizoma polygonati extract was used to replace the same amount of the Rehmannia glutinosa extract.
[0034] Animal experiment: After the SD male rats were adapted for one week, they were randomly divided into a control group, a model group, an example 1 group, a comparative example 1 group and a comparative example 2 group, 8 mice in each group.
[0035] The model group was injected intraperitoneally with 5wt% testosterone propionate (TP, dissolved in normal saline) at 5 mg / kg per day, and then was given normal saline by gavage at 15 ml / kg after the intraperitoneal injection, for 28 days of continuous administration; The blank control group was injected intraperitoneally with normal saline at 5 mg / kg per day, and then was given normal saline by gavage at 15 ml / kg after the intraperitoneal injection, for 28 days of continuous administration; The example 1 group, the comparative example 1 group and the comparative example 2 group were injected intraperitoneally with 5wt% testosterone propionate (TP, dissolved in normal saline) at 5 mg / kg per day, and then were given the corresponding liquid by gavage at 15 ml / kg after the intraperitoneal injection, for 18 days of continuous administration; The gavage liquid was obtained by dissolving the corresponding powder in normal saline at a concentration of 15 mg / ml.
[0036] After 16 hours of the last administration, the mice were weighed, and then the prostates of the mice were extracted and weighed, and then the prostate index was calculated according to the prostate wet weight, and the results are shown in Table 1. The prostate index=(prostate wet weight / body weight).
[0037] Table 1: Treatment effect of mice in each group
[0038] As can be seen from Table 1, compared with the blank control group, the prostate index of the mice in the model group was significantly increased, indicating that intraperitoneal injection of testosterone propionate caused significant enlargement of the prostate of the mice, and the modeling was successful. Compared with the model group, it can be seen that the example 1 group, the comparative example 1 group and the comparative example 2 group all had an improved treatment effect on the prostate hyperplasia, and compared with the comparative example 1 and the comparative example 2, the treatment effect of the example 1 group was the best. It can be seen that replacing the same efficacy of coix seed with poria cocos or replacing the same efficacy of polygonatum with rehmannia glutinosa will break the compatibility effect of the original prescription, thereby affecting the treatment effect. The effect of the comparative example 1 group was significantly worse than that of the example 1 group. Although coix seed and poria cocos belong to the same water-dampness-removing drugs, the characteristic of poria cocos is to invigorate the spleen and remove dampness, and its spleen-invigorating effect is stronger, which can prevent the generation of dampness from the source (spleen).
[0039] The present invention and its embodiments have been described above. This description is not restrictive, and the embodiments shown are only one of the embodiments of the present invention. The actual structure is not limited to this. In conclusion, if those skilled in the art are inspired by this description and design similar structures and embodiments without departing from the spirit of the present invention, they should all fall within the protection scope of the present invention.
Claims
1. The application of a traditional Chinese medicine composition in the preparation of a drug for treating prostate diseases, characterized in that, By weight, the traditional Chinese medicine composition comprises the following raw materials: 20-40 parts of Cistanche deserticola extract, 10-15 parts of ginseng extract, 40-50 parts of Rehmannia glutinosa extract, 20-30 parts of Astragalus membranaceus extract, 20-30 parts of Poria cocos extract, and 1-2 parts of maca extract.
2. The application according to claim 1, characterized in that, By weight, the traditional Chinese medicine composition comprises the following raw materials: 30 parts of Cistanche deserticola extract, 10 parts of ginseng extract, 45 parts of Rehmannia glutinosa extract, 25 parts of Astragalus membranaceus extract, 25 parts of Poria cocos extract, and 1 part of maca extract.
3. The application according to claim 1, characterized in that, By weight, the traditional Chinese medicine composition comprises the following raw materials: 20 parts of Cistanche deserticola extract, 15 parts of ginseng extract, 50 parts of Rehmannia glutinosa extract, 25 parts of Astragalus membranaceus extract, 30 parts of Poria cocos extract, and 2 parts of maca extract.
4. The application according to any one of claims 1 to 3, characterized in that, The extracts of Cistanche deserticola, ginseng, Rehmannia glutinosa, Astragalus membranaceus, Poria cocos, and maca were prepared by extracting the raw materials with solvents, followed by concentrating and drying the extracts.
5. The application according to claim 4, characterized in that, The solvent is water, alcohol, or an aqueous solution of alcohol.
6. The application according to any one of claims 1 to 5, characterized in that, The ginseng extract was replaced with red ginseng extract.
7. The application according to claims 1 to 6, characterized in that, The prostate diseases mentioned include benign prostatic hyperplasia (BPH).
8. A drug for treating prostate diseases, characterized in that, By weight, it is made from the following raw materials: 20-40 parts of Cistanche deserticola extract, 10-15 parts of ginseng extract, 40-50 parts of Rehmannia glutinosa extract, 20-30 parts of Astragalus membranaceus extract, 20-30 parts of Poria cocos extract, and 1-2 parts of maca extract.
9. A medicament for treating prostate diseases according to claim 8, characterized in that, By weight, it is made from the following raw materials: 30 parts of Cistanche deserticola extract, 10 parts of ginseng extract, 45 parts of Rehmannia glutinosa extract, 25 parts of Astragalus membranaceus extract, 25 parts of Poria cocos extract, and 1 part of maca extract.
10. A medicament for treating prostate diseases according to claim 8 or 9, characterized in that, The extracts of Cistanche deserticola, ginseng, Rehmannia glutinosa, Astragalus membranaceus, Poria cocos, and maca were prepared by extracting the raw materials with solvents, followed by concentrating and drying the extracts.